FGF21 and metabolic dysfunction-associated steatotic liver disease: Factors related with proinflammatory and profibrogenetic pathways such as leptin, adiponectin or FGF-21, which appears to be elevated in patients with NAFLD, are therefore a promising target for the treatment [71,72].